Mark Brantly

13.3k total citations
187 papers, 8.7k citations indexed

About

Mark Brantly is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Mark Brantly has authored 187 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Molecular Biology, 78 papers in Cancer Research and 42 papers in Oncology. Recurrent topics in Mark Brantly's work include Protease and Inhibitor Mechanisms (76 papers), Peptidase Inhibition and Analysis (40 papers) and Blood Coagulation and Thrombosis Mechanisms (27 papers). Mark Brantly is often cited by papers focused on Protease and Inhibitor Mechanisms (76 papers), Peptidase Inhibition and Analysis (40 papers) and Blood Coagulation and Thrombosis Mechanisms (27 papers). Mark Brantly collaborates with scholars based in United States, United Kingdom and Ireland. Mark Brantly's co-authors include Ronald G. Crystal, Toshihiro Nukiwa, James K. Stoller, Farshid N. Rouhani, Terence R. Flotte, Mark Holmes, Michael Courtney, David T. Curiel, Charlie Strange and Noel G. McElvaney and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Mark Brantly

181 papers receiving 8.4k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mark Brantly 3.0k 3.0k 2.5k 2.0k 1.4k 187 8.7k
Humphrey Gardner 1.5k 0.5× 4.5k 1.5× 2.7k 1.1× 1.2k 0.6× 1.2k 0.8× 102 9.0k
Florea Lupu 2.7k 0.9× 4.3k 1.4× 1.2k 0.5× 1.6k 0.8× 658 0.5× 182 12.3k
Elvira Pelosi 2.3k 0.8× 4.5k 1.5× 1.5k 0.6× 707 0.4× 417 0.3× 170 7.9k
Hiroaki Kataoka 1.3k 0.4× 4.0k 1.3× 1.9k 0.7× 725 0.4× 384 0.3× 295 8.1k
Lars Kjeldsen 1.1k 0.4× 3.4k 1.1× 1.2k 0.5× 884 0.4× 798 0.6× 133 9.7k
Lopa Mishra 1.5k 0.5× 3.8k 1.3× 2.7k 1.1× 819 0.4× 435 0.3× 169 7.8k
Kevin Shannon 871 0.3× 6.2k 2.1× 2.2k 0.9× 1.1k 0.6× 847 0.6× 276 12.5k
Yutaka Kondo 2.2k 0.7× 6.7k 2.2× 1.7k 0.7× 968 0.5× 694 0.5× 158 9.5k
Stanley Zucker 4.8k 1.6× 4.2k 1.4× 4.2k 1.7× 838 0.4× 325 0.2× 161 9.6k
Yusuke Nakamura 1.5k 0.5× 4.6k 1.5× 2.1k 0.8× 1.1k 0.5× 1.8k 1.3× 160 10.4k

Countries citing papers authored by Mark Brantly

Since Specialization
Citations

This map shows the geographic impact of Mark Brantly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Brantly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Brantly more than expected).

Fields of papers citing papers by Mark Brantly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Brantly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Brantly. The network helps show where Mark Brantly may publish in the future.

Co-authorship network of co-authors of Mark Brantly

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Brantly. A scholar is included among the top collaborators of Mark Brantly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Brantly. Mark Brantly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lu, Yuanqing, et al.. (2025). Pioglitazone reduces hepatic α-1 antitrypsin accumulation through autophagy and AMPK activation in α-1 antitrypsin-deficient mice. American Journal of Physiology-Gastrointestinal and Liver Physiology. 329(5). G585–G596. 1 indexed citations
2.
3.
Loomba, Rohit, Jeffrey Teckman, Veeral Ajmera, et al.. (2024). Review article: New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver disease. Alimentary Pharmacology & Therapeutics. 59(10). 1183–1195. 3 indexed citations
4.
Huo, Zhiguang, Virginia Clark, Thiago Beduschi, et al.. (2024). Sirtuin3 promotes the degradation of hepatic Z alpha-1 antitrypsin through lipophagy. Hepatology Communications. 8(2). 2 indexed citations
5.
Brantly, Mark, Brooks Kuhn, Ravi Mahadeva, et al.. (2024). Recombinant Alpha-1 Antitrypsin–Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 11(3). 282–292. 5 indexed citations
6.
Saltini, Cesare, Yan Ping Xin, Andrew J. Ghio, et al.. (2023). Lung microhaemorrhage drives oxidative/inflammatory damage in α1-antitrypsin deficiency. ERJ Open Research. 9(3). 662–2022. 2 indexed citations
7.
Lascano, Jorge, Qiang Xiao, Tammy Flagg, et al.. (2022). Correlation of alpha-1 antitrypsin levels and exosome associated neutrophil elastase endothelial injury in subjects with SARS-CoV2 infection. PLoS ONE. 17(9). e0274427–e0274427. 12 indexed citations
8.
Qi, Xiaoyan, et al.. (2021). Nicotine Exacerbates TAAD Formation Induced by Smooth Muscle-Specific Deletion of the TGF-β Receptor 2. Journal of Immunology Research. 2021. 1–17. 9 indexed citations
9.
Krotova, Karina, et al.. (2020). Neutrophil elastase promotes macrophage cell adhesion and cytokine production through the integrin-Src kinases pathway. Scientific Reports. 10(1). 49 indexed citations
10.
Zhang, Xiaojuan, Kien Pham, Ryan J. Schutte, et al.. (2019). Targeting the site encoded by SERPINA1*E342K for treating alpha‐1 antitrypsin deficiency‐associated liver diseases. FEBS Letters. 593(14). 1849–1862. 3 indexed citations
11.
Zhang, Xiaojuan, Kien Pham, Ryan J. Schutte, et al.. (2019). A Novel Small Molecule Inhibits Intrahepatocellular Accumulation of Z-Variant Alpha 1-Antitrypsin In Vitro and In Vivo. Cells. 8(12). 1586–1586. 13 indexed citations
12.
Fu, Chunhua, Yuanqing Lu, M. Williams, et al.. (2019). Emergency myelopoiesis contributes to immune cell exhaustion and pulmonary vascular remodelling. British Journal of Pharmacology. 178(1). 187–202. 12 indexed citations
13.
Sandhaus, Robert A., Gerard Turino, Mark Brantly, et al.. (2016). The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 3(3). 668–682. 140 indexed citations
14.
Wegman, Martin, Michael H. Guo, Douglas M. Bennion, et al.. (2014). Practicality of Intermittent Fasting in Humans and its Effect on Oxidative Stress and Genes Related to Aging and Metabolism. Rejuvenation Research. 18(2). 162–172. 97 indexed citations
15.
Campos, Michael, Friedrich Kueppers, James Stocks, et al.. (2013). Safety and Pharmacokinetics of 120 mg/kg versus 60 mg/kg Weekly Intravenous Infusions of Alpha-1 Proteinase Inhibitor in Alpha-1 Antitrypsin Deficiency: A Multicenter, Randomized, Double-Blind, Crossover Study (SPARK). COPD Journal of Chronic Obstructive Pulmonary Disease. 10(6). 687–695. 44 indexed citations
16.
Sandhaus, Robert A., et al.. (2013). Biochemical Efficacy and Safety of a New, Ready-to-Use, Liquid Alpha-1-Proteinase Inhibitor, GLASSIA (Alpha 1 -Proteinase Inhibitor (Human), Intravenous). COPD Journal of Chronic Obstructive Pulmonary Disease. 11(1). 17–25. 15 indexed citations
17.
Cruz, Pedro E., Christian Mueller, Travis Cossette, et al.. (2007). In vivo post-transcriptional gene silencing of α-1 antitrypsin by adeno-associated virus vectors expressing siRNA. Laboratory Investigation. 87(9). 893–902. 44 indexed citations
18.
Stocks, James, Mark Brantly, Alan R. Barker, et al.. (2006). Multi-Center Study: The Biochemical Efficacy, Safety and Tolerability of a New α1-Proteinase Inhibitor, Zemaira. COPD Journal of Chronic Obstructive Pulmonary Disease. 3(1). 17–23. 40 indexed citations
19.
Flotte, Terence R., Mark Brantly, L. Terry Spencer, et al.. (2004). Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV2-CB-hAAT) Gene Vector to AAT-Deficient Adults. Human Gene Therapy. 15(1). 93–128. 112 indexed citations
20.
Turino, Gerard M., Mark Brantly, Allen B. Cohen, et al.. (1996). Clinical Features of Individuals With PI*SZ Phenotype of Alpha 1-Antitrypsin Deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. American Journal of Respiratory and Critical Care Medicine. 154(6). 1718–1725. 128 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Humphrey Gardner Breakdown of academic impact, for papers by Florea Lupu Breakdown of academic impact, for papers by Elvira Pelosi Breakdown of academic impact, for papers by Hiroaki Kataoka Breakdown of academic impact, for papers by Lars Kjeldsen Breakdown of academic impact, for papers by Lopa Mishra Breakdown of academic impact, for papers by Kevin Shannon Breakdown of academic impact, for papers by Yutaka Kondo Breakdown of academic impact, for papers by Stanley Zucker Breakdown of academic impact, for papers by Yusuke Nakamura
Rankless by CCL
2026